Pharma Pioneer

Syena Begins Phase 1/2 Clinical Trial with First Patient Treated for Multiple Myeloma Using TCR-NK Cell Therapy

19 May 2024
2 min read

Syena, a subsidiary of Replay specializing in cell therapy, has initiated a Phase 1/2 clinical trial for patients with multiple myeloma. The trial involves the use of engineered T-Cell Receptor Natural Killer (TCR-NK) cells, which target the NY-ESO-1 antigen, a protein overexpressed in various cancer types. The treatment, NY-ESO-1 TCR/IL-15 NK, is based on the research of Professor Katy Rezvani from MD Anderson Cancer Center and is developed under an exclusive license from MD Anderson to Syena. The study will evaluate the safety and potential effectiveness of this novel cell therapy in up to 44 patients who have not responded to standard treatments.
The therapy is made from cord blood-derived NK cells that have been modified to express a receptor with enhanced affinity for the NY-ESO-1 antigen. This approach is considered groundbreaking due to the antigen's immunogenic properties and its presence on a wide range of cancer cells, making it an ideal target for immunotherapy.
Replay's leadership, including Adrian Woolfson and Lachlan MacKinnon, have expressed optimism about the potential of this therapy to fulfill the urgent medical need for readily available cell treatments. They highlighted the rapid progress of the clinical study and the significance of the NY-ESO-1 antigen in treating multiple myeloma with poor prognosis.
The clinical trial is registered on ClinicalTrials.gov with the identifier NCT06066359 for further details. Replay, which is headquartered in San Diego, California, is a genomic medicine company focused on advancing the field through innovative DNA technologies. The company has developed a high-capacity delivery platform and has established a business model that separates technology development from therapeutic applications across various product companies.
Replay has successfully raised $85 million in funding and is backed by a consortium of investors, including KKR, OMX Ventures, ARTIS Ventures, Lansdowne Partners, and the Bill and Melinda Gates Foundation. The company's mission is to redefine genomic medicine by overcoming current limitations and unlocking its full potential.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

First Patient Treated in Phase 2a Trial of IMM-1-104 for RAS-mutant Tumors
Pharma Pioneer
2 min read
First Patient Treated in Phase 2a Trial of IMM-1-104 for RAS-mutant Tumors
19 May 2024
Immuneering Corporation has commenced the Phase 2a segment of its Phase 1/2a clinical trial for IMM-1-104.
Read →
Plus Therapeutics Finishes Dosing in ReSPECT-LM Phase 1 Trial for Leptomeningeal Metastases
Pharma Pioneer
2 min read
Plus Therapeutics Finishes Dosing in ReSPECT-LM Phase 1 Trial for Leptomeningeal Metastases
19 May 2024
Plus Therapeutics has successfully dosed 18 patients in the ReSPECT-LM Phase 1 trial, which focuses on the treatment of leptomeningeal metastases (LM) from solid tumors using rhenium (186Re) obisbemeda.
Read →
Sonnet BioTherapeutics' SON-080 Phase 1b/2a CIPN Trial Meets Initial Safety Objectives
Pharma Pioneer
3 min read
Sonnet BioTherapeutics' SON-080 Phase 1b/2a CIPN Trial Meets Initial Safety Objectives
19 May 2024
The Data Safety Monitoring Board (DSMB) has reviewed the safety of SON-080 in the Phase 1b part of Sonnet's clinical trial.
Read →
FDA Lifts Partial Hold on Nurix's NX-2127 Phase 1 Trial
Pharma Pioneer
2 min read
FDA Lifts Partial Hold on Nurix's NX-2127 Phase 1 Trial
19 May 2024
Nurix Therapeutics has received a boost as the FDA lifted a partial clinical hold on their Phase 1a/1b study of NX-2127.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.